Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2022-06-16 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES ORAL PRESENTATION ON UPDATES FROM PHASE IIB CLINICAL TRIAL OF ASC22, A SUBCUTANEOUS PD-L1 ANTIBODY FOR FUNCTIONAL CURE OF CHRONIC HEPATITIS B AT EASL ILC 20
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding an oral presentation of clinical trial updates at a medical congress (International Liver Congress 2022). It includes details about the presentation, abstract number, session, and presenter, but does not contain any financial data, regulatory filings, or corporate governance information. The document is relatively short (4462 characters) and serves as an announcement of the presentation event rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a shareholder meeting material or voting result. The content is scientific/clinical trial update announcement. Given the available categories, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-06-16 English
AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 100% confidence The document is titled 'Amended and Restated Memorandum and Articles of Association' of World Houseware (Holdings) Limited, adopted by special resolution on 14 June 2022. It contains detailed company constitutional documents including the memorandum of association and articles of association, which define the company's objects, powers, share capital, and governance structure. This is a foundational legal document governing the company's operations and internal rules, not a financial report, announcement, or meeting material. It is not an Annual Report, Interim Report, or any financial disclosure. It is also not a proxy statement, voting results, or management change announcement. The document is lengthy (15,000 characters) and substantive, not a brief announcement or certification. Therefore, the best fitting category is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including constitutional documents like the memorandum and articles of association.
2022-06-14 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 14 JUNE 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on 14 June 2022. It details the voting outcomes on various resolutions including adoption of audited financial statements, re-election of directors, appointment of auditors, share allotment mandates, and amendments to the memorandum and articles of association. The document is not the full AGM materials or presentations but specifically the official voting results. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is about 5,000 characters, and it contains detailed voting results rather than just a brief notice or a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2022-06-14 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES U.S. FDA CLEARANCE OF CLINICAL TRIAL ON FXR AGONIST ASC42 FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the U.S. FDA clearance for a clinical trial of their drug candidate ASC42. It discusses clinical trial phases, drug development progress, and regulatory approval for a study. There are no financial statements, no detailed financial performance data, no voting results, no management or board changes, no earnings data, and no mention of a report being attached or published. The document is an announcement of a regulatory and clinical development milestone, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-06-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued shares, share options, and other related share capital information for Ascletis Pharma Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules. The content includes tables of share capital balances, movements in issued shares, share options, and confirmations related to share capital. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is regulatory in nature, reporting share capital movements and share option scheme details, which aligns with announcements about share capital changes rather than a full financial report or earnings release. Given the detailed nature of share capital movements and the absence of financial statements, this fits best under the category of Share Issue/Capital Change (SHA). The document length (5804 characters) supports it being a substantive report rather than a brief announcement or certification. Therefore, the classification is SHA with high confidence.
2022-06-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 May 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on share capital, issued shares, share options, and confirmations related to securities issued by World Houseware (Holdings) Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is regulatory in nature, reporting share capital and share issuance movements for the month ended 31 May 2022. It does not contain financial statements, management discussion, or earnings data. It is not an announcement of a report but a regulatory submission of share capital movements and confirmations. This type of document fits the category of Regulatory Filings (RNS), as it is a compliance report submitted to the exchange that does not fit other specific categories like share issue announcements (SHA) or director dealings (DIRS).
2022-06-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.